Vivos Therapeutics Inc. VVOS Archives - Page 3 of 4

ThursdayJul 01, 2021 12:36 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s founder and Chief Medical Officer Dr. G. Dave Singh shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product. “Dr. Singh’s primary goal with this book is to spread…

FridayJun 25, 2021 12:15 pm

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation The book mainly covers craniofacial growth and developmental Genetics It also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive Sleep Apnea (“OSA”) Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from…

WednesdayJun 09, 2021 10:55 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Unique System That Rebuilds Human Airway on Relentless Dentist Podcast

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), was featured in a recent episode of the Relentless Dentist podcast. The program features interviews with thought-provoking guests offering words of wisdom to help dentists gain the courage to develop the practices and lives of their dreams. Vivos Therapeutics CEO R. Kirk Huntsman joined the broadcast, hosted by certified High Performance Coach Dr. David Maloley, to discuss his professional background, his introduction to the company’s game-changing Vivos System(R), and his efforts to commercialize…

WednesdayMay 26, 2021 12:25 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder, CEO Authors Book Focused on Groundbreaking Work

Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach…

WednesdayApr 14, 2021 12:48 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in America and is board-certified in cardiovascular disease, nuclear cardiology and internal and integrative holistic medicine. “We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ chairman…

MondayApr 12, 2021 11:35 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Upcoming Emerging Growth Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), will be presenting at the Emerging Growth Conference this week. VVOS CEO Kirk Huntsman, along with chief financial officer Brad Amman and investor relations officer Ed Loew, will host the presentation, which is scheduled for Wednesday, April 14, at 9 a.m. EDT. Interested investors can obtain a free spectator pass. In addition, a replay of the presentation will be available on the Vivos website. To obtain a free spectator pass, visit https://ibn.fm/x2oti To view…

TuesdayMar 30, 2021 11:38 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new service will provide increased revenue through With this new training, Vivos expects to see additional revenue through increased cases and fees. The company expects its MyoCorrect service will become an effective treatment of OSA, thereby giving Vivos an additional competitive advantage in the OSA treatment…

FridayMar 26, 2021 9:26 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant achievements for the company was a full-year revenue increase of 15%; revenue for 2020 was $13.1 million compared to $11.4 million in 2019. Gross profit and margin was up for both the fourth quarter and…

TuesdayMar 23, 2021 11:18 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, Brad Amman, and Investor Relations Officer, Ed Loew, will be presenting at the event with their presentation scheduled to begin at 11:40 a.m. EST on Thursday, March 25, 2021. Investors interested in joining the Vivos presentation can register for a free spectator pass at https://ibn.fm/jQW0J.…

ThursdayMar 18, 2021 11:56 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Release, Discuss Q4, FY 2020 Financial Results

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), plans to release its fourth-quarter and full-year financial reports on March 25, 2021, after market close; the numbers will cover the period ending Dec. 31, 2020. The company has scheduled a conference call for 5 p.m. ET the same day. During the call, Vivos executives will discuss the financial report and provide an overview of the company's 2020 milestones and growth strategy moving forward. Interested parties can access the call by dialing (877) 451-6152;…

Site Search

Company Search

Tag: Vivos Therapeutics Inc. VVOS